[Antibody Craftsman Case] Successful Case of Antibody Distinguishing Specific Oxidized Cys
Production of antibodies through selection "in vitro" without animal immunity and verification of the specificity of the obtained antibodies.
Among the three Cys residues present in the DJ-1 protein, which is said to be involved in Parkinson's disease, we attempted to obtain antibodies that specifically recognize only the oxidized DJ-1 with the 106th Cys. This was done through the production of polyclonal antibodies via immunization in rabbits and monoclonal antibodies via immunization in mice, but we were unable to obtain the desired antibodies. Therefore, we used a peptide synthesized based on the surrounding sequence that includes the oxidized C106 as the antigen, and created conjugates with different carrier proteins and cross-linkers. As a result, we were able to identify clones that showed positive results for the oxidized C106 peptide and negative results for the reduced C106 peptide. [Case Summary] <Problem> ■ The methods of producing polyclonal antibodies through immunization in rabbits and monoclonal antibodies through immunization in mice did not yield the desired antibodies. <Result> ■ We were able to identify clones that showed positive results for the oxidized C106 peptide and negative results for the reduced C106 peptide. *For more details, please refer to the PDF document or feel free to contact us.
Inquire About This Product
basic information
【Antigen Design】 ■ The antigen uses peptides synthesized based on surrounding sequences containing oxidized C106. ■ Conjugates are created using carrier proteins and cross-linkers with different combinations. ■ As a negative control, peptides with the same sequence but containing reduced C106 are synthesized, coupled with carrier proteins, and conjugates are produced. *For more details, please refer to the PDF document or feel free to contact us.
Price range
Delivery Time
Applications/Examples of results
For more details, please refer to the PDF document or feel free to contact us.
catalog（1）
Download All Catalogs![[Antibody Case Study] Successful Case of Antibody Distinguishing Specific Oxidized Cys](https://image.mono.ipros.com/public/catalog/image/01/88c/638814/IPROS00637736271168714548.jpeg?w=120&h=170)
Company information
Gene Frontier has been expanding its business areas that contribute to the acceleration of biopharmaceuticals, including antibody drugs, and has been advancing the development of its unique technologies. Moving forward, we aim to accelerate our research and development and business development to achieve further growth on a global scale. We will continue to provide unique technologies and services for the development of innovative pharmaceuticals and diagnostic drugs, striving to be a trusted partner for our customers and contribute to 21st-century healthcare.